NC
SUPN icon

Northpointe Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Northpointe Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-35,222
Closed -$1.17M – 147
2018
Q4 		$1.17M Sell
35,222
-20,373
-37% -$876K 0.26% 142
2018
Q3 		$2.8M Sell
55,595
-2,992
-5% -$148K 0.4% 124
2018
Q2 		$3.51M Sell
58,587
-92,822
-61% -$4.81M 0.46% 93
2018
Q1 		$6.93M Sell
151,409
-88,488
-37% -$3.69M 0.87% 33
2017
Q4 		$9.56M Sell
239,897
-11,629
-5% -$460K 1.07% 25
2017
Q3 		$10.1M Sell
251,526
-26,200
-9% -$1.13M 1.07% 19
2017
Q2 		$12M Sell
277,726
-148,271
-35% -$5.28M 1.25% 14
2017
Q1 		$13.3M Sell
425,997
-104,186
-20% -$2.79M 1.45% 8
2016
Q4 		$13.4M Sell
530,183
-84,878
-14% -$1.9M 1.33% 16
2016
Q3 		$15.2M Sell
615,061
-146,142
-19% -$3.31M 1.58% 10
2016
Q2 		$15.5M Sell
761,203
-10,216
-1% -$181K 1.83% 2
2016
Q1 		$11.8M Buy
771,419
+186,666
+32% +$2.44M 1.46% 8
2015
Q4 		$8.2M Hold
584,753
– – 1.08% 23
2015
Q3 		$8.2M Sell
584,753
-303,926
-34% -$5.65M 1.07% 23
2015
Q2 		$15.1M Sell
888,679
-319,579
-26% -$4.55M 1.77% 5
2015
Q1 		$14.6M Buy
1,208,258
+227,196
+23% +$2.15M 1.58% 6
2014
Q4 		$8.14M Sell
981,062
-153,385
-14% -$1.29M 0.98% 25
2014
Q3 		$9.86M Buy
1,134,447
+114,628
+11% +$1.04M 1.05% 23
2014
Q2 		$11.2M Sell
1,019,819
-50,079
-5% -$446K 1.08% 20
2014
Q1 		$9.56M Buy
+1,069,898
New +$9.85M 0.97% 42

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northpointe Capital's SUPN Position: Q1 2019 in Review

Northpointe Capital sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 35,222 shares — an estimated $1.17M sold.

Northpointe Capital first reported a position in SUPN in Q1 2014 and held it in 20 quarters. The position peaked at $15.5M in Q2 2016. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Northpointe Capital reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Northpointe Capital sold 35,222 Supernus Pharmaceuticals shares in Q1 2019, an estimated $1.17M.
  • Northpointe Capital first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 20 quarters.
  • Northpointe Capital's Supernus Pharmaceuticals position peaked at $15.5M in Q2 2016.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Northpointe Capital's 13F filing for Q1 2019, filed 17 Apr 2019.